Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer

Oncology

Volumn 75, Issue 3-4, 2008, Pages 145-151

  Jarmalaite, Sonata ^a,b   Jankevicius, Feliksas ^a   Kurgonaite, Kristina ^a   Suziedelis, Kestutis ^a   Mutanen, Pertti ^b   Husgafvel Pursiainen, Kirsti ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

Bladder cancer; DNA methylation; Epigenetics; Tumour aggressiveness; Tumour suppressor gene

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA;

ADULT; AGED; ALKYLATION; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; HYPERMETHYLATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); URINARY BLADDER NEOPLASMS;

EID: 52549088093     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000158665     Document Type: Article

References (37)

1. Kirkali Z, Chan T, Manoharan M, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 suppl 1):4-34.
2. Kurtinaitis J, Aleknaviciene B, Smailyte G: The main results of cancer control in Lithuania; in Transitional Report 2005. Vilnius, Lithuanian Cancer Registry, 2006.
3. Chopin DK, Gattegno B: Superficial bladder tumors. Eur Urol 2002;42:533-541.
4. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-373.
5. Josephson DY, Pasin E, Stein JP: Superficial bladder cancer. 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther 2006;6:1723-1734.
6. Wu X-R: Urothelial tumorigenesis: a tale of divergent pathways. Nature 2005;5:713-726.
7. Schulz WA: Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-1518.
8. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
9. Veltri RW, Makarov DV: Nucleic acid-based marker approaches to urological cancers. Urol Oncol 2006;24:510-527.
10. Goessl C, Muller M, Straub B, Miller K: DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002;41:668-676.
11. ARF and methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006;339:790-796.
12. Friedrich MG, Chandrasoma S, Siegmund KD, et al: Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005;41:2769-2778.
13. Catto JW, Azzouzi AR, Rehman I, et al: Promoter hypermethylation is associated with tumor location, stage and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005;23:2903-2910.
14. Tada Y, Wada M, Taguchi K, et al: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62:4048-4053.
15. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-8663.
16. Cairns P: Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 2007;7:531-543.
17. Sobin LH, Wittekind C: TNM Classification of Malignant Tumors, ed 5. New York, Wiley, 1997.
18. Mostofi FK, Sobin LH, Torlini H: Histological typing of urinary bladder tumors;in International Histological Classification of Tumors, No 10. Geneva, World Health Organization, 1973.
19. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
20. Jarmalaite S, Kannio A, Anttila S, Lazutka JR, Husgafvel-Pursiainen K: Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003;106:913-918.
21. Lemeta S, Jarmalaite S, Pylkkanen L, Bohling T, Husgafvel-Pursiainen K: Preferential loss of the noninprinted allele for the ZAC1 tumor suppressor gene in human capillary hemangioblastoma. J Neuropathol Exp Neurol 2007;66:860-867.
22. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
23. Virmani AK, Rathi A, Zöchbauer-Müller S, et al: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-1307.
24. Burbee DG, Forgacs E, Zöchbauer-Müller S: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699.
25. Katzenellenbogen RA, Baylin SB, Herman JG: Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-4353.
26. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
27. Hoque MO, Begum S, Topalogu O, et al: Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004.
28. Marsit CJ, Karagas MR, Danaee H, et al: Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006;27:112-116.
29. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P: Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-1893.
30. Chan MWY, Chan LW, Tang NLS, et al: Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-616.
31. Chan MWY, Chan LW, Tang NLS, et al: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-470.
32. Dhawan D, Hamdy FC, Rehman I, et al: Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006;209:336-343.
33. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S: DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis. J Urol 2005;173:1767-1771.
34. Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT: Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007;28:1745-1751.
35. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
36. Friedrich MG, Weisenberger DJ, Cheng JC, et al: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457-7465.
37. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JWF: Methylation urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006;25:1984-1988.